Atypical Parkinsonism clinical trials at UCSF
2 in progress, 1 open to eligible people
Atypical parkinsonism includes diseases that affect movement and are not the same as Parkinson's disease. UCSF is testing if a drug called zoledronic acid can reduce fractures in affected individuals. The study is home-based and includes a placebo group for comparison.
Parkinson's and Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
San Francisco, California and other locations
AMX0035 and Progressive Supranuclear Palsy
Sorry, in progress, not accepting new patients
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
San Francisco, California and other locations
Last updated: